COMPAZINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Oct 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is an oral tablet small-molecule antipsychotic and antiemetic approved in 1956 by GSK. The drug's exact mechanism of action and approved indications are not specified in available data, but historical use includes treatment of nausea, vomiting, and psychotic disorders. It represents a legacy therapeutic from the mid-20th century antipsychotic era.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating a contracting team focused on generic transition and maintenance revenue.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COMPAZINE presents limited career growth opportunities given its LOE-approaching status and lack of linked job openings. Roles available are primarily in legacy product management, generic defense, and regulatory wind-down activities.
Brand ManagerProduct Manager
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.